hemotag® assessment for short-term outcomes of heart failure

Conditions: Heart Failure (HF)

Summary: evaluation of the hemotag® system in a less controlled environment and concurrently develop the system for use by patients with heart failure.

the overall objective of research is to test, adapt, refine and validate the hemotag® system to be used outside the usual medical care environments to reduce hospital readmissions.

Eligibility criteria:
inclusion criteria: * age greater than or equal to 22 years old. * an index hospital admission for adhf presenting with symptoms, clinical signs, and chest x-ray (cxr) findings of pulmonary congestion, receiving iv diuretics or vasoactive drugs and having a bnp \> 350 or nt-pro bnp \> 1800 pg/ml. * able to give informed consent. * participant's residence has adequate cellular data coverage. * participants with previous diagnosis of left ventricular ejection fraction (lvef) \<40% prior to the index hospitalization must have been treated for at least 90 days prior to enrollment with diuretics and beta-blocker (unless intolerant or contraindicated) and an ace inhibitor or arb or arni (unless intolerant or contraindicated). exclusion criteria: * participants unable to provide informed, voluntary decision to participate in research study as determined by the investigator. (exclude participants who necessitate the involvement of a legally authorized representative.) * terminal condition with life expectancy less than 6 months as determined by investigator. * participants with cardiac tamponade or constrictive pericarditis. * participants with left ventricular assistance device (lvad device) or had a cardiac transplantation or listed for transplantation. * implantation of a crt (cardiac resynchronization therapy) device during index hospitalization or intent to implant a crt device. * presence of hemodynamically significant mitral and/or aortic valve disease, except mitral regurgitation secondary to left ventricular dilatation, as determined by investigator. * presence of hemodynamically significant obstructive lesions of left ventricular outflow tract, including aortic and sub-aortic stenosis, as determined by investigator. * severe primary pulmonary, renal or hepatic disease, as determined by investigator. * women of childbearing age (age \<50). * history of pulmonary embolism of less than 3 months. * dialysis dependent or dialysis initiation expected within three months. * chronic home iv therapy or cardiac inotropes or diuretics. * physical deformity in the chest area or lesion that may prevent proper hemotag application or adjustment. * illness/ condition which may be aggravated or cause significant discomfort by the application of the hemotag (skin issues, e.g. intolerance to use of skin electrodes). * impaired cognitive ability or any other state that may prevent full compliance with the study protocol, according to investigator's assessment. * congenital heart malformations (complex, or uncorrected congenital heart disease). * participant enrolled in another interventional study (observational or registries are not excluded). * participant hf is managed remotely with another monitoring device or program (for example: pulmonary/ lt atrial pressure monitoring, lung fluid monitoring. bnp/pro-bnp or bioimpedance or icd or biventricular pacemaker with impedance monitoring will be allowed unless it is part of another research protocol). * prisoners and wards of the state. * inability to provide informed consent (must speak english or spanish or creole).